Two Sigma Advisers LP Sells 181,200 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)

Two Sigma Advisers LP decreased its position in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 884,300 shares of the company's stock after selling 181,200 shares during the period. Two Sigma Advisers LP owned approximately 1.25% of C4 Therapeutics worth $3,183,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CCCC. Rhumbline Advisers boosted its holdings in C4 Therapeutics by 4.6% in the fourth quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock worth $360,000 after purchasing an additional 4,366 shares during the last quarter. Sei Investments Co. bought a new position in shares of C4 Therapeutics in the fourth quarter worth approximately $45,000. American Century Companies Inc. increased its stake in shares of C4 Therapeutics by 8.5% in the fourth quarter. American Century Companies Inc. now owns 132,832 shares of the company's stock worth $478,000 after purchasing an additional 10,459 shares in the last quarter. Balyasny Asset Management L.P. raised its position in shares of C4 Therapeutics by 115.4% during the 4th quarter. Balyasny Asset Management L.P. now owns 42,533 shares of the company's stock valued at $153,000 after purchasing an additional 22,789 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of C4 Therapeutics by 49.4% during the 4th quarter. Jane Street Group LLC now owns 152,774 shares of the company's stock valued at $550,000 after buying an additional 50,523 shares in the last quarter. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Stock Down 6.4%

NASDAQ CCCC traded down $0.09 during trading hours on Friday, reaching $1.24. The company's stock had a trading volume of 836,365 shares, compared to its average volume of 1,385,303. C4 Therapeutics, Inc. has a 1 year low of $1.09 and a 1 year high of $7.66. The company has a market capitalization of $87.69 million, a price-to-earnings ratio of -0.73 and a beta of 3.10. The firm's 50-day moving average price is $1.44 and its 200-day moving average price is $2.77.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.11. The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $3.54 million. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. Equities research analysts anticipate that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, UBS Group upgraded C4 Therapeutics to a "hold" rating in a research note on Friday, February 14th.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.